New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesityPRNewsWire • 10/09/26
Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare PlatformThe Motley Fool • 10/08/26
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?Zacks Investment Research • 10/08/26
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge cautionMarket Watch • 10/08/26
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A PremiumSeeking Alpha • 10/08/26
Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond ZepboundThe Motley Fool • 10/07/26
Lilly's Worst Entry Points Were Its Most Hyped Approvals Mounjaro and Zepbound24/7 Wall Street • 10/07/26
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 10/06/26
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/06/26
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its StockThe Motley Fool • 10/05/26
FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line SettingZacks Investment Research • 10/05/26
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditionsPRNewsWire • 10/05/26